Firebrick Pharma Past Earnings Performance
Past criteria checks 0/6
Firebrick Pharma's earnings have been declining at an average annual rate of -14.1%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 55.8% per year.
Key information
-14.1%
Earnings growth rate
14.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 55.8% |
| Return on equity | -55.6% |
| Net Margin | -42.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation
Aug 14
We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
May 02We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully
Dec 14Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth
Aug 30Revenue & Expenses Breakdown
How Firebrick Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -1 | 2 | 2 |
| 31 Mar 24 | 2 | -3 | 2 | 3 |
| 31 Dec 23 | 2 | -5 | 2 | 4 |
| 30 Sep 23 | 1 | -6 | 2 | 4 |
| 30 Jun 23 | 0 | -7 | 2 | 4 |
| 31 Mar 23 | 1 | -6 | 2 | 4 |
| 31 Dec 22 | 1 | -5 | 2 | 4 |
| 30 Sep 22 | 1 | -5 | 2 | 3 |
| 30 Jun 22 | 1 | -4 | 2 | 2 |
| 31 Mar 22 | 1 | -3 | 2 | 2 |
| 31 Dec 21 | 0 | -3 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 2 | 1 |
| 30 Jun 20 | 1 | -1 | 0 | 2 |
Quality Earnings: FRE is currently unprofitable.
Growing Profit Margin: FRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FRE is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare FRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FRE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: FRE has a negative Return on Equity (-55.59%), as it is currently unprofitable.